Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest mechanical ventilation Stories

2012-03-21 06:24:26

HAMPTON, N.J., March 21, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the Center for Devices and Radiological Health (CDRH) branch of the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for compatibility of its INOMAX drug-delivery systems with three additional respiratory care devices. The INOMAX DS and the INOMAX DSIR have now been validated...

2012-03-19 06:25:13

JERUSALEM and NEEDHAM, Mass., March 19, 2012 /PRNewswire/ -- Oridion (SIX Swiss Exchange: ORIDN), creator of the Integrated Pulmonary Index(TM), one of the Smart Capnography(TM) family of decision-support solutions, today announced results of an attendee survey conducted at the October 2011 annual meeting of the American Society for Anesthesiologists (ASA) conference in Chicago. Respondents showed a clear preference for monitoring ventilation using capnography over other options. Results of...

2012-03-06 18:01:00

New Drug Helps Pre-Term Infants Breathe LA JOLLA, Calif., March 6, 2012 /PRNewswire-USNewswire/ -- Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin® (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome. "I am excited that our scientific findings will help save lives," said Charles Cochrane, M.D., professor emeritus at Scripps Research. "Many years of work in our basic...

2012-03-06 15:10:00

WARRINGTON, Pa., March 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use in neonatal...

2012-02-27 09:17:00

HAMPTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD). The trial, which commenced in December 2009, enrolled its last patient six weeks ahead of schedule. The...

2012-02-17 10:56:19

Fever control using external cooling in sedated patients with septic shock is safe and decreases vasopressor requirements and early mortality, according to a new study from researchers in France. "The benefits and risks of fever control in patients with severe sepsis remains a matter of controversy," said lead author Frédérique Schortgen, MD, PhD, of the Henri Mondor Hospital in Créteil, France. "In our study, external cooling to achieve normothermia...

2012-02-08 06:45:00

WARRINGTON, Pa., Feb. 8, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has entered into a definitive agreement with Lacey Manufacturing, a unit of Precision Engineered Products, LLC to manufacture and supply product for the commercial introduction of AFECTAIR®. AFECTAIR was recently cleared for commercialization in the United States and...

2012-02-02 06:45:00

WARRINGTON, Pa., Feb. 2, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced AFECTAIR® is now registered with the Food and Drug Administration (FDA) and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient interface technology that simplifies delivery of aerosolized medications to patients requiring ventilator support. "We are...

2012-01-20 11:09:37

Extracorporeal membrane oxygenation (ECMO) support in awake, non-intubated patients may be an effective strategy for bridging patients to lung transplantation, according to a new study from Germany. "As waiting times for donor organs continue to increase, so does the need for bridging strategies for patients with end-stage lung disease awaiting transplantation," said Marius M. Hoeper, MD, professor of medicine at the Hannover Medical School in Hannover, Germany. "Our study shows that ECMO...

2011-12-13 08:30:00

CHICAGO and BOSTON, Dec. 13, 2011 Real time monitoring of the adequacy of ventilation (i.e. how much carbon dioxide a patient breathes out) could save patients' lives, recent research suggests. Just ask Lenore Alexander, whose daughter Leah had elective surgery for pectus carinatum, a fairly common condition where the sternum protrudes forward caused by an overgrowth of cartilage. [For the YouTube video by The Empowered Patient Coalition on Leah and other children who died in...